Latest Administration News

Titan Minerals Limited has launched a transaction-specific prospectus offering 4 million new options to its underwriter, exercisable at A$0.70 and expiring in January 2027. The offer, which raises no immediate funds, could inject approximately A$2.8 million upon option exercise.

Challenger Gold Limited’s Preliminary Feasibility Study for the Hualilan Toll Milling Project outlines a robust three-year operation delivering 450,000 tonnes of gold-silver ore to Austral Gold’s Casposo plant, with strong economics and low upfront capital.

Challenger Gold has completed a Pre-Feasibility Study for toll milling at its Hualilan Gold Project, revealing strong economics, low capital requirements, and a swift payback period. The study underscores the project's potential to generate significant cash flow over three years through a toll milling arrangement with Austral Gold.

Anax Metals has issued a detailed clarification on its recent $3.3 million convertible note placement with Mineral Development Partners, addressing inconsistencies in shareholder approval disclosures and announcing strengthened compliance measures.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

Mayne Pharma rebuffs Cosette's claim of a material adverse change in their merger scheme and secures FDA clearance on regulatory concerns, maintaining its commitment to the deal's completion.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

James Hardie Industries is set to terminate its American Depositary Share program following its merger with The AZEK Company and direct NYSE listing, simplifying its share structure for investors.

Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.

Neurotech International has reported positive human pharmacokinetic results for NTI164, a cannabinoid formulation designed for paediatric neurological disorders, confirming rapid absorption and a non-intoxicating profile.

Radiopharm Theranostics has unveiled encouraging preclinical results for its Lu177-B7H3 monoclonal antibody, RV01, paving the way for a mid-2025 Investigational New Drug submission and a Phase 1 trial later that year.

Lumos Diagnostics has reached 50% recruitment of bacterial positive patients in its pivotal FebriDx CLIA waiver clinical study, setting the stage for a planned FDA submission in late 2025 and unlocking a substantial US market opportunity.